These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24818626)

  • 1. Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study.
    Sendur MA; Güven GS; Yorgun H; Ateş AH; Canpolat U; Sunman H; Karahan S; Kaya B; Aytemir K
    Anadolu Kardiyol Derg; 2014 Jun; 14(4):363-9. PubMed ID: 24818626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive Drugs Aliskiren, Nebivolol, and Olmesartan Reduce Hypertension by Reducing Endothelial Microparticles and Regulating Angiogenesis.
    Jain M; Bhosale V; Tripathi D; Singh H; Pal N; Hanif K; Jagavelu K
    J Cardiovasc Pharmacol; 2017 Sep; 70(3):176-183. PubMed ID: 28498232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.
    Koc Y; Mazi E; Sakaci T; Basturk T; Damar AB; Ahbap E; Unsal A; Borlu F
    Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1389-94. PubMed ID: 22288300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.
    Wei D; He WY; Lv QZ
    CNS Neurosci Ther; 2012 May; 18(5):400-5. PubMed ID: 22533725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
    Erdoğan O; Ertem B; Altun A
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):310-3. PubMed ID: 21543293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension.
    Bulur S; Ozhan H; Erden I; Alemdar R; Aydin M; Caglar O; Basar C; Ordu S
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):29-33. PubMed ID: 20975532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.
    Oparil S; Lee J; Karki S; Melino M
    J Cardiovasc Pharmacol; 2009 Nov; 54(5):427-36. PubMed ID: 19730391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
    Punzi HA
    Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between oxidative stress, activator protein-1, inflammatory, total antioxidant status and artery stiffness and the efficacy of olmesartan in elderly patients with mild-to-moderate essential hypertension.
    Liu Q; Han L; Du Q; Zhang M; Zhou S; Shen X
    Clin Exp Hypertens; 2016; 38(4):365-9. PubMed ID: 27159403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
    Mallion JM; Heagerty A; Laeis P
    J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase.
    Takiguchi S; Ayaori M; Uto-Kondo H; Iizuka M; Sasaki M; Komatsu T; Takase B; Adachi T; Ohsuzu F; Ikewaki K
    Hypertens Res; 2011 Jun; 34(6):686-92. PubMed ID: 21307868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Functional and biochemical characteristics of the vasodilator effects of nebivolol in patients with arterial hypertension].
    Gel'tser BI; Kotel'niko v VN; Savchenko SV
    Ter Arkh; 2002; 74(12):34-7. PubMed ID: 12577837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.
    Malacco E; Omboni S; Volpe M; Auteri A; Zanchetti A;
    J Hypertens; 2010 Nov; 28(11):2342-50. PubMed ID: 20829713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy.
    Rosendorff C; Dubiel R; Xu J; Chavanu KJ
    Am J Cardiol; 2009 Aug; 104(3):359-65. PubMed ID: 19616668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of treatment with olmesartan on ambulatory blood pressure monitoring parameters in patients with arterial hypertension].
    Bregvadze TR; Tseluĭko VI; Mishchuk NE
    Georgian Med News; 2013 Dec; (225):60-7. PubMed ID: 24423678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.